In vivo and in vitro studies of microsphere pancreatic supplements
- PMID: 2457072
- DOI: 10.1097/00005176-198811001-00006
In vivo and in vitro studies of microsphere pancreatic supplements
Abstract
Over the past 5 years, the Leeds Regional Cystic Fibrosis (CF) Unit has provided comprehensive annual assessments of CF patients that include dietary assessments and fat absorption studies. Enteric-coated microsphere pancreatic enzyme preparations (microsphere preparations) were compared to conventional enzymes as therapeutic agents for these patients. Presently in the U.K., two microsphere preparations are licensed for use and a further two products are likely to receive licenses in the near future. The success of these preparations is dependent on the ability of the microsphere coating to resist dissolution until the pH exceeds approximately 5.5 and thus prevent inactivation of lipase in the acid environment of the stomach. A study comparing Pancrex V Forte, a conventional enzyme preparation, to three microsphere preparations, Pancrease, Creon, and pancreatin Merck, confirmed the superiority of Pancrease and Creon over Pancrex V Forte and pancreatin Merck with regard to control of symptoms, and nitrogen and fat absorption. Because of differences in the physical characteristics of various microsphere preparations, the dissolution rates of Pancrease, Creon, and pancreatin Merck were compared in vitro. In aqueous buffers, striking differences among the preparations were seen at pH 5.5; whereas only 25% of available lipase was released from Creon, both Pancrease and pancreatin Merck show almost complete dissolution at this pH. Only at pH 6.5 and above do all three preparations show complete dissolution. In duodenal juice, as in aqueous buffers, lipase release from Creon takes place at a lower rate than with the other two preparations until pH 6.0 or higher is attained.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Comparison of four pancreatic extracts in cystic fibrosis.Arch Dis Child. 1987 Jun;62(6):564-8. doi: 10.1136/adc.62.6.564. Arch Dis Child. 1987. PMID: 3304172 Free PMC article. Clinical Trial.
-
Efficacy of pancreatic enzyme supplementation in children with cystic fibrosis: comparison of two preparations by random crossover study and a retrospective study of the same patients at two different ages.J Pediatr Gastroenterol Nutr. 1988;7 Suppl 1:S40-5. J Pediatr Gastroenterol Nutr. 1988. PMID: 3042938 Clinical Trial.
-
In vitro dissolution profiles of enteric-coated microsphere/microtablet pancreatin preparations at different pH values.Aliment Pharmacol Ther. 1996 Oct;10(5):771-5. doi: 10.1046/j.1365-2036.1996.55197000.x. Aliment Pharmacol Ther. 1996. PMID: 8899086
-
Development of pancreatic enzyme microsphere technology and US findings with Pancrease in the treatment of chronic pancreatitis.Int J Pancreatol. 1989;5 Suppl:31-6. Int J Pancreatol. 1989. PMID: 2702248 Review.
-
CREON (Pancrelipase Delayed-Release Capsules) for the treatment of exocrine pancreatic insufficiency.Adv Ther. 2010 Dec;27(12):895-916. doi: 10.1007/s12325-010-0085-7. Epub 2010 Nov 15. Adv Ther. 2010. PMID: 21086085 Review.
Cited by
-
Pancreatic enzyme replacement therapy for people with cystic fibrosis.Cochrane Database Syst Rev. 2020 Aug 5;8(8):CD008227. doi: 10.1002/14651858.CD008227.pub4. Cochrane Database Syst Rev. 2020. PMID: 32761612 Free PMC article.
-
Abdominal pain in cystic fibrosis.J R Soc Med. 1995;88 Suppl 25(Suppl 25):9-17. J R Soc Med. 1995. PMID: 7776329 Free PMC article. Review. No abstract available.
-
Pancreatic enzyme replacement therapy for people with cystic fibrosis.Cochrane Database Syst Rev. 2016 Nov 23;11(11):CD008227. doi: 10.1002/14651858.CD008227.pub3. Cochrane Database Syst Rev. 2016. Update in: Cochrane Database Syst Rev. 2020 Aug 5;8:CD008227. doi: 10.1002/14651858.CD008227.pub4. PMID: 27878805 Free PMC article. Updated.
-
In Vitro Comparison of Physical Parameters, Enzyme Activity, Acid Resistance, and pH Dissolution Characteristics of Enteric-Coated Pancreatic Enzyme Preparations: Implications for Clinical Variability and Pharmacy Substitution.J Pediatr Pharmacol Ther. 2007 Apr;12(2):115-28. doi: 10.5863/1551-6776-12.2.115. J Pediatr Pharmacol Ther. 2007. PMID: 23055848 Free PMC article.
-
Pancreatic enzyme replacement therapy for pancreatic exocrine insufficiency in the 21(st) century.World J Gastroenterol. 2014 Sep 7;20(33):11467-85. doi: 10.3748/wjg.v20.i33.11467. World J Gastroenterol. 2014. PMID: 25206255 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous